{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:16:40Z","timestamp":1792631800825,"version":"4.5.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T00:00:00Z","timestamp":1541462400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1038\/s41584-018-0111-8","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T12:47:34Z","timestamp":1541508454000},"page":"693-703","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":179,"title":["Hydroxychloroquine retinopathy \u2014 implications of research advances for rheumatology care"],"prefix":"10.1038","volume":"14","author":[{"given":"April","family":"Jorge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Ung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald B.","family":"Melles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyon K.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,6]]},"reference":[{"key":"111_CR1","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2006.068676","volume":"66","author":"GS Alarcon","year":"2007","unstructured":"Alarcon, G. S. et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann. Rheum. Dis. 66, 1168\u20131172 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"111_CR2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","volume":"69","author":"G Ruiz-Irastorza","year":"2010","unstructured":"Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P. & Khamashta, M. A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a\u00a0systematic review. Ann. Rheum. Dis. 69, 20\u201328 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"111_CR3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0961203306071872","volume":"15","author":"G Ruiz-Irastorza","year":"2006","unstructured":"Ruiz-Irastorza, G. et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15, 577\u2013583 (2006).","journal-title":"Lupus"},{"key":"111_CR4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJM199101173240303","volume":"324","author":"The Canadian Hydroxychloroquine Study Group","year":"1991","unstructured":"The Canadian Hydroxychloroquine Study Group. A\u00a0Randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N. Engl. J. Med. 324, 150\u2013154 (1991).","journal-title":"N. Engl. J. Med."},{"key":"111_CR5","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/art.24538","volume":"61","author":"GJ Pons-Estel","year":"2009","unstructured":"Pons-Estel, G. J. et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 61, 830\u2013839 (2009).","journal-title":"Arthritis Rheum."},{"key":"111_CR6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11926-010-0141-y","volume":"13","author":"M Petri","year":"2011","unstructured":"Petri, M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in\u00a0antiphospholipid antibody-positive patients. Curr.\u00a0Rheumatol. Rep. 13, 77\u201380 (2011).","journal-title":"Curr. Rheumatol. Rep."},{"key":"111_CR7","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1002\/art.22159","volume":"54","author":"ME Clowse","year":"2006","unstructured":"Clowse, M. E., Magder, L., Witter, F. & Petri, M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 54, 3640\u20133647 (2006).","journal-title":"Arthritis Rheum."},{"key":"111_CR8","unstructured":"Jorge, A. & Ramsey-Goldman, R. in Systemic Lupus Erythematosus 117\u2013135 (Oxford Univ. Press, 2016)."},{"key":"111_CR9","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1177\/0961203312450084","volume":"21","author":"E Cairoli","year":"2012","unstructured":"Cairoli, E., Rebella, M., Danese, N., Garra, V. & Borba, E. F. Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus 21, 1178\u20131182 (2012).","journal-title":"Lupus"},{"key":"111_CR10","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/rheumatology\/ker514","volume":"51","author":"GJ Pons-Estel","year":"2012","unstructured":"Pons-Estel, G. J. et al. Anti-malarials exert a protective effect while Mestizo patients are at increased risk of\u00a0developing SLE renal disease: data from a Latin-American cohort. Rheumatology (Oxford) 51, 1293\u20131298 (2012).","journal-title":"Rheumatology (Oxford)"},{"key":"111_CR11","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrrheum.2012.106","volume":"8","author":"DJ Wallace","year":"2012","unstructured":"Wallace, D. J., Gudsoorkar, V. S., Weisman, M. H. & Venuturupalli, S. R. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat. Rev. Rheumatol. 8, 522\u2013533 (2012).","journal-title":"Nat. Rev. Rheumatol."},{"key":"111_CR12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1303006","volume":"369","author":"JR O\u2019Dell","year":"2013","unstructured":"O\u2019Dell, J. R. et al. Therapies for active rheumatoid arthritis after methotrexate failure. N. Engl. J. Med. 369, 307\u2013318 (2013).","journal-title":"N. Engl. J. Med."},{"key":"111_CR13","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/art.34498","volume":"64","author":"LW Moreland","year":"2012","unstructured":"Moreland, L. W. et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the Treatment of Early Aggressive Rheumatoid Arthritis trial. Arthritis Rheum. 64, 2824\u20132835 (2012).","journal-title":"Arthritis Rheum."},{"key":"111_CR14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7326\/M16-0713","volume":"167","author":"N Bansback","year":"2017","unstructured":"Bansback, N. et al. Triple therapy versus biologic therapy for active rheumatoid arthritis: a cost-effectiveness analysis. Ann. Int. Med. 167, 8\u201316 (2017).","journal-title":"Ann. Int. Med."},{"key":"111_CR15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/annrheumdis-2017-211836","volume":"77","author":"C Rempenault","year":"2018","unstructured":"Rempenault, C. et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann. Rheum. Dis. 77, 98\u2013103 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"111_CR16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jama.298.2.187","volume":"298","author":"MC Wasko","year":"2007","unstructured":"Wasko, M. C. et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 298, 187\u2013193 (2007).","journal-title":"JAMA"},{"key":"111_CR17","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/rheumatology\/keu451","volume":"54","author":"YM Chen","year":"2015","unstructured":"Chen, Y. M. et al. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study. Rheumatology (Oxford) 54, 1244\u20131249 (2015).","journal-title":"Rheumatology (Oxford)"},{"key":"111_CR18","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.ophtha.2016.12.021","volume":"124","author":"RA Braslow","year":"2017","unstructured":"Braslow, R. A., Shiloach, M. & Macsai, M. S. Adherence to hydroxychloroquine dosing guidelines by rheumatologists: an electronic medical record-based study in an integrated health care system. Ophthalmology 124, 604\u2013608 (2017).","journal-title":"Ophthalmology"},{"key":"111_CR19","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","volume":"132","author":"RB Melles","year":"2014","unstructured":"Melles, R. B. & Marmor, M. F. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 132, 1453\u20131460 (2014).","journal-title":"JAMA Ophthalmol."},{"key":"111_CR20","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ajo.2016.06.045","volume":"170","author":"RB Melles","year":"2016","unstructured":"Melles, R. B. & Marmor, M. F. The prevalence of hydroxychloroquine retinopathy and toxic dosing, and\u00a0the role of the ophthalmologist in reducing both. Am. J. Ophthalmol. 170, 240 (2016).","journal-title":"Am. J. Ophthalmol."},{"key":"111_CR21","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ophtha.2014.10.015","volume":"122","author":"JL Johnston","year":"2015","unstructured":"Johnston, J. L., Darvill, P. & Thomson, G. T. Spectral-domain optical coherence tomography in hydroxychloroquine retinopathy. Ophthalmology 122, 651\u2013652 (2015).","journal-title":"Ophthalmology"},{"key":"111_CR22","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3346\/jkms.2017.32.3.522","volume":"32","author":"DR Eo","year":"2017","unstructured":"Eo, D. R. et al. Frequency and clinical characteristics of hydroxychloroquine retinopathy in Korean patients with rheumatologic diseases. J. Kor. Med. Sci. 32, 522\u2013527 (2017).","journal-title":"J. Kor. Med. Sci."},{"key":"111_CR23","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.ophtha.2015.01.014","volume":"122","author":"DH Lee","year":"2015","unstructured":"Lee, D. H. et al. Pericentral hydroxychloroquine retinopathy in Korean patients. Ophthalmology 122, 1252\u20131256 (2015).","journal-title":"Ophthalmology"},{"key":"111_CR24","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2147\/OPTH.S163451","volume":"12","author":"DJ Browning","year":"2018","unstructured":"Browning, D. J. & Lee, C. Somatotype, the risk of hydroxychloroquine retinopathy, and safe daily dosing guidelines. Clin. Ophthalmol. (Auckland, N. Z.) 12, 811\u2013818 (2018).","journal-title":"Clin. Ophthalmol. (Auckland, N. Z.)"},{"key":"111_CR25","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0161-6420(03)00409-3","volume":"110","author":"I Mavrikakis","year":"2003","unstructured":"Mavrikakis, I. et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine. Ophthalmology 110, 1321\u20131326 (2003).","journal-title":"Ophthalmology"},{"key":"111_CR26","first-page":"808","volume":"26","author":"C Wang","year":"1999","unstructured":"Wang, C. et al. Discontinuation of antimalarial drugs in systemic lupus erythematosus. J. Rheumatol. 26, 808\u2013815 (1999).","journal-title":"J. Rheumatol"},{"key":"111_CR27","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/art.1780400817","volume":"40","author":"GD Levy","year":"1997","unstructured":"Levy, G. D. et al. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum. 40, 1482\u20131486 (1997).","journal-title":"Arthritis Rheum."},{"key":"111_CR28","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archopht.124.12.1729","volume":"124","author":"M Elder","year":"2006","unstructured":"Elder, M., Rahman, A. M. & McLay, J. Early paracentral visual field loss in patients taking hydroxychloroquine. Arch. Ophthalmol. 124, 1729\u20131733 (2006).","journal-title":"Arch. Ophthalmol."},{"key":"111_CR29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0002-9343(88)90358-0","volume":"85","author":"M Easterbrook","year":"1988","unstructured":"Easterbrook, M. Ocular effects and safety of antimalarial agents. Am. J. Med. 85, 23\u201329 (1988).","journal-title":"Am. J. Med."},{"key":"111_CR30","first-page":"109","volume":"101","author":"PV Mills","year":"1981","unstructured":"Mills, P. V., Beck, M. & Power, B. J. Assessment of the retinal toxicity of hydroxychloroquine. Trans. Ophthalmol. Soc. UK 101, 109\u2013113 (1981).","journal-title":"Trans. Ophthalmol. Soc. UK"},{"key":"111_CR31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/0002-9343(83)91270-6","volume":"75","author":"CL Bell","year":"1983","unstructured":"Bell, C. L. Hydroxychloroquine sulfate in rheumatoid arthritis: long-term response rate and predictive parameters. Am. J. Med. 75, 46\u201351 (1983).","journal-title":"Am. J. Med."},{"key":"111_CR32","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/acr.20133","volume":"62","author":"F Wolfe","year":"2010","unstructured":"Wolfe, F. & Marmor, M. F. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. (Hoboken) 62, 775\u2013784 (2010).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"111_CR33","first-page":"380","volume":"30","author":"JA Jover","year":"2012","unstructured":"Jover, J. A. et al. Long-term use of antimalarial drugs in rheumatic diseases. Clin. Exp. Rheumatol. 30, 380\u2013387 (2012).","journal-title":"Clin. Exp. Rheumatol."},{"key":"111_CR34","first-page":"95","volume":"32","author":"ASMW Tsang","year":"2014","unstructured":"Tsang, A. S. M. W., Bultink, I. E. & Voskuyl, A. E. Long-term evaluation of antimalarials in a Dutch SLE cohort: intolerance and other reasons for non-use. Clin. Exp. Rheumatol. 32, 95\u2013100 (2014).","journal-title":"Clin. Exp. Rheumatol."},{"key":"111_CR35","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/archophthalmol.2011.371","volume":"130","author":"MF Marmor","year":"2012","unstructured":"Marmor, M. F. Comparison of screening procedures in hydroxychloroquine toxicity. Arch. Ophthalmol. 130, 461\u2013469 (2012).","journal-title":"Arch. Ophthalmol."},{"key":"111_CR36","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2147\/OPTH.S66527","volume":"8","author":"DJ Browning","year":"2014","unstructured":"Browning, D. J. & Lee, C. Relative sensitivity and specificity of 10\u201312 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy. Clin. Ophthalmol. 8, 1389\u20131399 (2014).","journal-title":"Clin. Ophthalmol."},{"key":"111_CR37","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1001\/jamaophthalmol.2013.4835","volume":"131","author":"MF Marmor","year":"2013","unstructured":"Marmor, M. F. Fundus autofluorescence is not the best early screen for hydroxychloroquine toxicity. JAMA Ophthalmol. 131, 1487\u20131488 (2013).","journal-title":"JAMA Ophthalmol."},{"key":"111_CR38","unstructured":"U.S. Centers for Medicare & Medicaid Services. Physician fee schedule search. CMS.gov \n                    https:\/\/www.cms.gov\/apps\/physician-fee-schedule\/search\/search-criteria.aspx\n                    \n                   (2018)."},{"key":"111_CR39","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","volume":"123","author":"MF Marmor","year":"2016","unstructured":"Marmor, M. F. et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123, 1386\u20131394 (2016).","journal-title":"Ophthalmology"},{"key":"111_CR40","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1097\/IAE.0000000000001151","volume":"36","author":"MF Marmor","year":"2016","unstructured":"Marmor, M. F. The demise of the bull\u2019s eye (screening for hydroxychloroquine retinopathy). Retina 36, 1803\u20131805 (2016).","journal-title":"Retina"},{"key":"111_CR41","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ophtha.2014.07.056","volume":"122","author":"C Cukras","year":"2015","unstructured":"Cukras, C. et al. Subjective and objective screening tests for hydroxychloroquine toxicity. Ophthalmology 122, 356\u2013366 (2015).","journal-title":"Ophthalmology"},{"key":"111_CR42","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaophthalmol.2014.1099","volume":"132","author":"MF Marmor","year":"2014","unstructured":"Marmor, M. F. & Hu, J. Effect of disease stage on progression of hydroxychloroquine retinopathy. JAMA\u00a0Ophthalmol. 132, 1105\u20131112 (2014).","journal-title":"JAMA Ophthalmol."},{"key":"111_CR43","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ophtha.2014.07.018","volume":"122","author":"RB Melles","year":"2015","unstructured":"Melles, R. B. & Marmor, M. F. Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology 122, 110\u2013116 (2015).","journal-title":"Ophthalmology"},{"key":"111_CR44","doi-asserted-by":"crossref","first-page":"ix","DOI":"10.1016\/j.ajo.2016.03.044","volume":"166","author":"DJ Browning","year":"2016","unstructured":"Browning, D. J. The prevalence of hydroxychloroquine retinopathy and toxic dosing, and the role of the ophthalmologist in reducing both. Am J. Ophthalmol. 166, ix\u2013xi (2016).","journal-title":"Am J. Ophthalmol."},{"key":"111_CR45","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3928\/23258160-20170130-01","volume":"48","author":"MF Marmor","year":"2017","unstructured":"Marmor, M. F. Hydroxychloroquine screening alert: change is in the wind. Ophthalm. Surg. Lasers Imag. Retina 48, 96\u201398 (2017).","journal-title":"Ophthalm. Surg. Lasers Imag. Retina"},{"key":"111_CR46","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/0006-2952(67)90233-X","volume":"16","author":"EW McChesney","year":"1967","unstructured":"McChesney, E. W., Shekosky, J. M. & Hernandez, P. H. Metabolism of chloroquine 3-14C in the rhesus monkey. Biochem. Pharmacol. 16, 2444\u20132447 (1967).","journal-title":"Biochem. Pharmacol."},{"key":"111_CR47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0002-9343(83)91265-2","volume":"75","author":"EW McChesney","year":"1983","unstructured":"McChesney, E. W. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am. J. Med. 75, 11\u201318 (1983).","journal-title":"Am. J. Med."},{"key":"111_CR48","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0002-9343(83)91267-6","volume":"75","author":"HN Bernstein","year":"1983","unstructured":"Bernstein, H. N. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am. J. Med. 75, 25\u201334 (1983).","journal-title":"Am. J. Med."},{"key":"111_CR49","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0002-9343(83)91264-0","volume":"75","author":"AH MacKenzie","year":"1983","unstructured":"MacKenzie, A. H. Pharmacologic action of 4-aminoquinolone compounds. Am. J. Med. 75, 5\u201310 (1983).","journal-title":"Am. J. Med."},{"key":"111_CR50","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00007691-198907000-00001","volume":"11","author":"EO Titus","year":"1989","unstructured":"Titus, E. O. Recent developments in the understanding of the pharmacokinetics and mechanism of action of chloroquine. Ther. Drug Monitor. 11, 369\u2013379 (1989).","journal-title":"Ther. Drug Monitor."},{"key":"111_CR51","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.berh.2013.07.001","volume":"27","author":"N Costedoat-Chalumeau","year":"2013","unstructured":"Costedoat-Chalumeau, N. et al. Adherence to treatment in systemic lupus erythematosus patients. Best Pract. Res. Clin. Rheumatol. 27, 329\u2013340 (2013).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"111_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.01.002","author":"CH Feldman","year":"2018","unstructured":"Feldman, C. H. et al. Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus. Semin. Arthritis Rheum. \n                    https:\/\/doi.org\/10.1016\/j.semarthrit.2018.01.002\n                    \n                   (2018).","journal-title":"Semin. Arthritis Rheum."},{"key":"111_CR53","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/aje\/kwp107","volume":"170","author":"B Lau","year":"2009","unstructured":"Lau, B., Cole, S. R. & Gange, S. J. Competing risk\u00a0regression models for epidemiologic data. Am.\u00a0J.\u00a0Epidemiol. 170, 244\u2013256 (2009).","journal-title":"Am. J. Epidemiol."},{"key":"111_CR54","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/rheumatology\/kex412","volume":"57","author":"AM Jorge","year":"2018","unstructured":"Jorge, A. M., Lu, N., Zhang, Y., Rai, S. K. & Choi, H. K. Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999\u20132014). Rheumatology (Oxford) 57, 337\u2013344 (2018).","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl. 10","key":"111_CR55","first-page":"2990","volume":"69","author":"N Lu","year":"2017","unstructured":"Lu, N., Choi, H. K., Jorge, A. & Zhang, Y. Is risk of retinopathy among hydroxychloroquine users of SLE patients accurate? A simulation study accounting for competing risk of death [abstract]. Arthritis Rheumatol. 69 (Suppl. 10), 2990 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"111_CR56","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/rheumatology\/kev357","volume":"55","author":"HJ Ding","year":"2016","unstructured":"Ding, H. J., Denniston, A. K., Rao, V. K. & Gordon, C. Hydroxychloroquine-related retinal toxicity. Rheumatology (Oxford) 55, 957\u2013967 (2016).","journal-title":"Rheumatology (Oxford)"},{"key":"111_CR57","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1083\/jcb.33.1.61","volume":"33","author":"RW Young","year":"1967","unstructured":"Young, R. W. The renewal of photoreceptor cell outer segments. J. Cell Biol. 33, 61\u201372 (1967).","journal-title":"J. Cell Biol."},{"key":"111_CR58","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1083\/jcb.42.2.392","volume":"42","author":"RW Young","year":"1969","unstructured":"Young, R. W. & Bok, D. Participation of the retinal pigment epithelium in the rod outer segment renewal process. J. Cell Biol. 42, 392\u2013403 (1969).","journal-title":"J. Cell Biol."},{"key":"111_CR59","doi-asserted-by":"crossref","first-page":"12005","DOI":"10.1073\/pnas.0704756104","volume":"104","author":"EF Nandrot","year":"2007","unstructured":"Nandrot, E. F. et al. Essential role for MFG-E8 as ligand for \u03b1v\u03b25 integrin in diurnal retinal phagocytosis. Proc. Natl Acad. Sci. USA 104, 12005\u201312010 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"111_CR60","doi-asserted-by":"crossref","first-page":"802","DOI":"10.2174\/156652410793937813","volume":"10","author":"J Sparrrow","year":"2010","unstructured":"Sparrrow, J., Hicks, D. & Hamel, C. The retinal pigment epithelium in health and disease. Curr. Mol. Med. 10, 802\u2013823 (2010).","journal-title":"Curr. Mol. Med."},{"key":"111_CR61","doi-asserted-by":"crossref","first-page":"11370","DOI":"10.1021\/bi001061c","volume":"39","author":"JK McBee","year":"2000","unstructured":"McBee, J. K. et al. Isomerization of all-trans-retinol to cis-retinols in bovine retinal pigment epithelial cells: dependence on the specificity of retinoid-binding proteins. Biochemistry 39, 11370\u201311380 (2000).","journal-title":"Biochemistry"},{"key":"111_CR62","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/jbt.21696","volume":"29","author":"NM Korthagen","year":"2015","unstructured":"Korthagen, N. M. et al. Chloroquine and hydroxychloroquine increase retinal pigment epithelial layer permeability. J. Biochem. Mol. Toxicol. 29, 299\u2013304 (2015).","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"111_CR63","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1167\/iovs.10-5278","volume":"51","author":"YH Yoon","year":"2010","unstructured":"Yoon, Y. H. et al. Induction of lysosomal dilatation, arrested autophagy, and cell death by chloroquine in cultured ARPE-19 cells. Invest. Ophthalmol. Vis. Sci. 51, 6030\u20136037 (2010).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"Suppl. 1","key":"111_CR64","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1177\/0961203396005001031","volume":"5","author":"R Fox","year":"1996","unstructured":"Fox, R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus 5(Suppl. 1), S4\u2013S10 (1996).","journal-title":"Lupus"},{"key":"111_CR65","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1034\/j.1600-0463.2002.100606.x","volume":"110","author":"SP Sundelin","year":"2002","unstructured":"Sundelin, S. P. & Terman, A. Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells. APMIS 110, 481\u2013489 (2002).","journal-title":"APMIS"},{"key":"111_CR66","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/archophthalmol.2010.321","volume":"129","author":"M Michaelides","year":"2011","unstructured":"Michaelides, M., Stover, N. B., Francis, P. J. & Weleber, R. G. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Arch. Ophthalmol. 129, 30\u201339 (2011).","journal-title":"Arch. Ophthalmol."},{"key":"111_CR67","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/jps.24663","volume":"105","author":"C Xu","year":"2016","unstructured":"Xu, C. et al. Chloroquine and hydroxychloroquine are novel inhibitors of human organic anion transporting polypeptide 1A2. J. Pharm. Sci. 105, 884\u2013890 (2016).","journal-title":"J. Pharm. Sci."},{"key":"111_CR68","doi-asserted-by":"crossref","first-page":"26684","DOI":"10.1074\/jbc.M804505200","volume":"283","author":"A Maeda","year":"2008","unstructured":"Maeda, A., Maeda, T., Golczak, M. & Palczewski, K. Retinopathy in mice induced by disrupted all-trans-retinal clearance. J. Biol. Chem. 283, 26684\u201326693 (2008).","journal-title":"J. Biol. Chem."},{"key":"111_CR69","first-page":"1158","volume":"17","author":"AR Rosenthal","year":"1978","unstructured":"Rosenthal, A. R., Kolb, H., Bergsma, D., Huxsoll, D. & Hopkins, J. L. Chloroquine retinopathy in the rhesus monkey. Invest. Ophthalmol. Vis. Sci. 17, 1158\u20131175 (1978).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"111_CR70","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0002-9394(72)90137-7","volume":"73","author":"MS Ramsey","year":"1972","unstructured":"Ramsey, M. S. & Fine, B. S. Chloroquine toxicity in the human eye. Histopathologic observations by electron microscopy. Am. J. Ophthalmol. 73, 229\u2013235 (1972).","journal-title":"Am. J. Ophthalmol."},{"key":"111_CR71","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/eye.2009.65","volume":"24","author":"S Pasadhika","year":"2010","unstructured":"Pasadhika, S. & Fishman, G. A. Effects of chronic exposure to hydroxychloroquine or chloroquine on inner retinal structures. Eye (Lond.) 24, 340\u2013346 (2010).","journal-title":"Eye (Lond.)"},{"key":"111_CR72","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/eye.2010.21","volume":"24","author":"S Pasadhika","year":"2010","unstructured":"Pasadhika, S., Fishman, G. A., Choi, D. & Shahidi, M. Selective thinning of the perifoveal inner retina as an early sign of hydroxychloroquine retinal toxicity. Eye\u00a0(Lond.) 24, 756\u2013762 (2010).","journal-title":"Eye (Lond.)"},{"key":"111_CR73","first-page":"2919","volume":"27","author":"Canadian Rheumatology Association","year":"2000","unstructured":"Canadian Rheumatology Association. Canadian Consensus Conference on hydroxychloroquine. J.\u00a0Rheumatol. 27, 2919\u20132921 (2000).","journal-title":"J. Rheumatol"},{"key":"111_CR74","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0161-6420(02)01168-5","volume":"109","author":"MF Marmor","year":"2002","unstructured":"Marmor, M. F., Carr, R. E., Easterbrook, M., Farjo, A. A. & Mieler, W. F. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a\u00a0report by the American Academy of Ophthalmology. Opthamology 109, 1377\u20131382 (2002).","journal-title":"Opthamology"},{"key":"111_CR75","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/ard.2007.070367","volume":"67","author":"G Bertsias","year":"2008","unstructured":"Bertsias, G. et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for international clinical studies including therapeutics. Ann. Rheum. Dis. 67, 195\u2013205 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"111_CR76","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.3899\/jrheum.150379","volume":"42","author":"L Durcan","year":"2015","unstructured":"Durcan, L., Clarke, W. A., Magder, L. S. & Petri, M. Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J. Rheumatol. 42, 2092\u20132097 (2015).","journal-title":"J. Rheumatol."},{"key":"111_CR77","first-page":"1","volume":"39","author":"CD Fryar","year":"2016","unstructured":"Fryar, C. D., Gu, Q., Ogden, C. L. & Flegal, K. M. Anthropometric reference data for children and adults: United States, 2011\u20132014. Vital Health Stat. 3 39, 1\u201346 (2016).","journal-title":"Vital Health Stat. 3"},{"key":"111_CR78","unstructured":"Health and Social Care Information Centre. National statistics: statistics on obesity, physical activity and diet. NHS Digital \n                    https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/statistics-on-obesity-physical-activity-and-diet\/statistics-on-obesity-physical-activity-and-diet-england-2018\n                    \n                   (2016)."},{"key":"111_CR79","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2147\/OPTH.S66531","volume":"8","author":"DJ Browning","year":"2014","unstructured":"Browning, D. J., Lee, C. & Rotberg, D. The impact of different algorithms for ideal body weight on screening\u00a0for hydroxychloroquine retinopathy in women. Clin. Ophthalmol. 8, 1401\u20131407 (2014).","journal-title":"Clin. Ophthalmol."},{"key":"111_CR80","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1177\/106002807400801104","volume":"8","author":"B Devine","year":"1974","unstructured":"Devine, B. Clinical pharmacy case studies: case\u00a0number 25: gentamicin therapy. Drug Intell. Clin.\u00a0Pharm. 8, 650\u2013655 (1974).","journal-title":"Drug Intell. Clin. Pharm."},{"key":"111_CR81","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s00296-017-3782-6","volume":"7","author":"MA Gianfrancesco","year":"2017","unstructured":"Gianfrancesco, M. A. et al. Hydroxychloroquine dosing in immune-mediated diseases: implications for\u00a0patient safety. Rheumatol. Int. 7, 1611\u20131618 (2017).","journal-title":"Rheumatol. Int."},{"key":"111_CR82","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s10067-018-4116-0","volume":"37","author":"RB Melles","year":"2018","unstructured":"Melles, R. B., Jorge, A. M., Marmor, M. F., Zhang, Y. & Choi, H. K. Sharp decline in hydroxychloroquine dosing-analysis of 17,797 initiators from 2007 to 2016. Clin. Rheumatol. 37, 1853\u20131859 (2018).","journal-title":"Clin. Rheumatol."},{"key":"111_CR83","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13075-018-1634-8","volume":"20","author":"AM Jorge","year":"2018","unstructured":"Jorge, A. M. et al. Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. Arthritis Res. Ther. 20, 133 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"111_CR84","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ajo.2015.07.012","volume":"160","author":"LS Leung","year":"2015","unstructured":"Leung, L. S., Neal, J. W., Wakelee, H. A., Sequist, L. V. & Marmor, M. F. Rapid onset of retinal toxicity from high-dose hydroxychloroquine given for cancer therapy. Am J. Ophthalmol. 160, 799\u2013805 (2015).","journal-title":"Am J. Ophthalmol."},{"key":"111_CR85","unstructured":"The Royal College of Ophthalmologists. Clinical guidelines: hydroxychloroquine and chloroquine retinopathy: recommendations on screening. RCOphth\u00a0\n                    https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2018\/07\/Hydroxychloroquine-and-Chloroquine-Retinopathy-Screening-Guideline-Recommendations.pdf\n                    \n                   (2018)."},{"key":"111_CR86","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000200","volume":"4","author":"A Duarte-Garcia","year":"2017","unstructured":"Duarte-Garcia, A., Barr, E., Magder, L. S. & Petri, M. Predictors of incident proteinuria among patients with SLE. Lupus Sci. Med. 4, e000200 (2017).","journal-title":"Lupus Sci. Med."},{"key":"111_CR87","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/acr.22837","volume":"68","author":"CC Mok","year":"2016","unstructured":"Mok, C. C. et al. Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: a longitudinal cohort analysis. Arthritis Care Res. (Hoboken) 68, 1295\u20131302 (2016).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"111_CR88","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1002\/art.22156","volume":"54","author":"N Costedoat-Chalumeau","year":"2006","unstructured":"Costedoat-Chalumeau, N. et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 54, 3284\u20133290 (2006).","journal-title":"Arthritis Rheum."},{"key":"111_CR89","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/acr.22636","volume":"67","author":"CH Feldman","year":"2015","unstructured":"Feldman, C. H., Yazdany, J., Guan, H., Solomon, D. H. & Costenbader, K. H. Medication nonadherence is associated with increased subsequent acute care utilization among medicaid beneficiaries with systemic lupus erythematosus. Arthritis Care Res. (Hoboken) 67, 1712\u20131721 (2015).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"111_CR90","unstructured":"The Royal College of Ophthalmologists. Hydroxychloroquine and ocular toxicity recommendations on screening. BAD \n                    http:\/\/www.bad.org.uk\/shared\/get-file.ashx?id=774&itemtype=document\n                    \n                   (2009)."},{"key":"111_CR91","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ophtha.2010.11.017","volume":"118","author":"MF Marmor","year":"2011","unstructured":"Marmor, M. F., Kellner, U., Lai, T. Y., Lyons, J. S. & Mieler, W. F. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 118, 415\u2013422 (2011).","journal-title":"Ophthalmology"},{"key":"111_CR92","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","volume":"71","author":"GK Bertsias","year":"2012","unstructured":"Bertsias, G. K. et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann. Rheum. Dis. 71, 1771\u20131782 (2012).","journal-title":"Ann. Rheum. Dis."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41584-018-0111-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-018-0111-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-018-0111-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:18:18Z","timestamp":1684621098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-018-0111-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,6]]},"references-count":92,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["111"],"URL":"https:\/\/doi.org\/10.1038\/s41584-018-0111-8","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,6]]},"assertion":[{"value":"6 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}